LT3452039T - Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriais - Google Patents
Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriaisInfo
- Publication number
- LT3452039T LT3452039T LTEPPCT/US2017/031142T LTUS2017031142T LT3452039T LT 3452039 T LT3452039 T LT 3452039T LT US2017031142 T LTUS2017031142 T LT US2017031142T LT 3452039 T LT3452039 T LT 3452039T
- Authority
- LT
- Lithuania
- Prior art keywords
- deuteronated
- treatment
- hair loss
- jak inhibitors
- loss disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662331827P | 2016-05-04 | 2016-05-04 | |
| US201662338869P | 2016-05-19 | 2016-05-19 | |
| US201662418774P | 2016-11-07 | 2016-11-07 | |
| US201662419237P | 2016-11-08 | 2016-11-08 | |
| US201662434404P | 2016-12-14 | 2016-12-14 | |
| US201762466358P | 2017-03-02 | 2017-03-02 | |
| US201762492758P | 2017-05-01 | 2017-05-01 | |
| PCT/US2017/031142 WO2017192905A1 (en) | 2016-05-04 | 2017-05-04 | Treatment of hair loss disorders with deuterated jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3452039T true LT3452039T (lt) | 2024-10-25 |
Family
ID=60203616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2017/031142T LT3452039T (lt) | 2016-05-04 | 2017-05-04 | Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriais |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10561659B2 (enExample) |
| EP (2) | EP4424367A3 (enExample) |
| JP (3) | JP7145080B2 (enExample) |
| KR (3) | KR20250070139A (enExample) |
| CN (1) | CN109069493A (enExample) |
| AU (3) | AU2017261286B2 (enExample) |
| BR (1) | BR112018072339A2 (enExample) |
| CA (1) | CA3022519A1 (enExample) |
| DK (1) | DK3452039T3 (enExample) |
| ES (1) | ES2988629T3 (enExample) |
| FI (1) | FI3452039T3 (enExample) |
| HR (1) | HRP20241345T1 (enExample) |
| HU (1) | HUE068643T2 (enExample) |
| LT (1) | LT3452039T (enExample) |
| MX (6) | MX388054B (enExample) |
| PL (1) | PL3452039T3 (enExample) |
| PT (1) | PT3452039T (enExample) |
| RS (1) | RS66006B1 (enExample) |
| SI (1) | SI3452039T1 (enExample) |
| SM (1) | SMT202400389T1 (enExample) |
| WO (1) | WO2017192905A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20241345T1 (hr) | 2016-05-04 | 2024-12-20 | Sun Pharmaceutical Industries, Inc. | Liječenje poremećaja gubitka kose deuteriranim inhibitorima jak |
| CN113906032A (zh) * | 2019-02-06 | 2022-01-07 | 康塞特医药品有限公司 | 用于制备对映异构体富集的jak抑制剂的方法 |
| WO2021236139A1 (en) | 2020-05-21 | 2021-11-25 | Concert Pharmaceuticals, Inc. | Novel deuterated jak inhibitor and uses thereof |
| EP4236956A1 (en) * | 2020-10-28 | 2023-09-06 | Sun Pharmaceutical Industries, Inc. | Regimens for the treatment of hair loss disorders with deuterated jak inhibitors |
| CN116916927A (zh) * | 2020-10-28 | 2023-10-20 | 太阳医药工业公司 | 用于用氘化jak抑制剂治疗脱发症的方案 |
| CN112402615A (zh) * | 2020-11-11 | 2021-02-26 | 长沙晶易医药科技有限公司 | 一种用于治疗斑秃的复方外用制剂及其制备方法 |
| AU2022328272A1 (en) | 2021-08-11 | 2024-02-22 | Sun Pharmaceutical Industries, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
| WO2023018954A1 (en) | 2021-08-12 | 2023-02-16 | Concert Pharmaceuticals, Inc. | Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors |
| US20250275977A1 (en) | 2022-05-04 | 2025-09-04 | Sun Pharmaceutical Industries, Inc. | Dosage regimens for treatment with deuterated jak inhibitors |
| US12364699B2 (en) * | 2023-10-10 | 2025-07-22 | Sun Pharmaceuticals Industries, Inc. | Method of treating hair loss disorders |
| US12247034B1 (en) * | 2024-04-19 | 2025-03-11 | Sun Pharmaceutical Industries, Inc. | Crystalline form of deuruxolitinib phosphate |
| US20260021047A1 (en) * | 2024-07-19 | 2026-01-22 | Sun Pharmaceutical Industries, Inc. | Oral formulations of deuruxolitinib |
| US20260027120A1 (en) * | 2024-07-25 | 2026-01-29 | Sun Pharmaceutical Industries, Inc. | Methods of treatment of jak inhibition responsive conditions with deuterated jak inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| BR0209325A (pt) | 2001-05-03 | 2004-07-20 | Hoffmann La Roche | Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo |
| BRPI0516170A (pt) | 2004-09-29 | 2008-08-26 | Cordis Corp | formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina |
| TWI630207B (zh) | 2005-12-13 | 2018-07-21 | 英塞特控股公司 | 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶 |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| TWI665200B (zh) | 2009-01-15 | 2019-07-11 | 英塞特公司 | 製造ｊａｋ抑制劑之方法及相關中間化合物 |
| PL2635299T3 (pl) * | 2010-11-02 | 2020-03-31 | The Trustees Of Columbia University In The City Of New York | Sposoby leczenia zaburzeń utraty włosów |
| US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| PL2830662T3 (pl) | 2012-03-29 | 2019-02-28 | The Trustees Of Columbia University In The City Of New York | Sposoby leczenia zaburzeń utraty włosów |
| ES2867048T3 (es) | 2012-06-15 | 2021-10-20 | Concert Pharmaceuticals Inc | Derivados deuterados de ruxolitinib |
| BR112015001839A2 (pt) * | 2012-07-30 | 2017-07-04 | Concert Pharmaceuticals Inc | ibrutinibe deuterado |
| PL2919766T3 (pl) | 2012-11-15 | 2021-10-04 | Incyte Holdings Corporation | Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu |
| JP6367545B2 (ja) | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| CN110229159B (zh) * | 2013-12-18 | 2021-08-24 | 康塞特医药品有限公司 | 卢索替尼的氘代衍生物 |
| WO2015120110A2 (en) * | 2014-02-07 | 2015-08-13 | Auspex Pharmaceuticals, Inc. | Novel pharmaceutical formulations |
| HRP20241345T1 (hr) | 2016-05-04 | 2024-12-20 | Sun Pharmaceutical Industries, Inc. | Liječenje poremećaja gubitka kose deuteriranim inhibitorima jak |
-
2017
- 2017-05-04 HR HRP20241345TT patent/HRP20241345T1/hr unknown
- 2017-05-04 KR KR1020257015799A patent/KR20250070139A/ko active Pending
- 2017-05-04 WO PCT/US2017/031142 patent/WO2017192905A1/en not_active Ceased
- 2017-05-04 EP EP24175652.7A patent/EP4424367A3/en active Pending
- 2017-05-04 HU HUE17793380A patent/HUE068643T2/hu unknown
- 2017-05-04 RS RS20241081A patent/RS66006B1/sr unknown
- 2017-05-04 LT LTEPPCT/US2017/031142T patent/LT3452039T/lt unknown
- 2017-05-04 SM SM20240389T patent/SMT202400389T1/it unknown
- 2017-05-04 PL PL17793380.1T patent/PL3452039T3/pl unknown
- 2017-05-04 FI FIEP17793380.1T patent/FI3452039T3/fi active
- 2017-05-04 SI SI201731552T patent/SI3452039T1/sl unknown
- 2017-05-04 KR KR1020237019001A patent/KR102810262B1/ko active Active
- 2017-05-04 CA CA3022519A patent/CA3022519A1/en active Pending
- 2017-05-04 AU AU2017261286A patent/AU2017261286B2/en active Active
- 2017-05-04 ES ES17793380T patent/ES2988629T3/es active Active
- 2017-05-04 CN CN201780027427.2A patent/CN109069493A/zh active Pending
- 2017-05-04 US US16/098,338 patent/US10561659B2/en active Active
- 2017-05-04 PT PT177933801T patent/PT3452039T/pt unknown
- 2017-05-04 DK DK17793380.1T patent/DK3452039T3/da active
- 2017-05-04 EP EP17793380.1A patent/EP3452039B1/en active Active
- 2017-05-04 KR KR1020187034867A patent/KR20190003711A/ko not_active Ceased
- 2017-05-04 MX MX2018013347A patent/MX388054B/es unknown
- 2017-05-04 BR BR112018072339-8A patent/BR112018072339A2/pt not_active Application Discontinuation
- 2017-05-04 JP JP2018557837A patent/JP7145080B2/ja active Active
-
2018
- 2018-10-31 MX MX2023002324A patent/MX2023002324A/es unknown
- 2018-10-31 MX MX2023002323A patent/MX2023002323A/es unknown
- 2018-10-31 MX MX2023002321A patent/MX2023002321A/es unknown
- 2018-10-31 MX MX2021014175A patent/MX2021014175A/es unknown
- 2018-10-31 MX MX2023002325A patent/MX2023002325A/es unknown
-
2019
- 2019-12-05 US US16/704,402 patent/US12076323B2/en active Active
-
2022
- 2022-09-16 JP JP2022147751A patent/JP7586868B2/ja active Active
-
2023
- 2023-02-24 AU AU2023201112A patent/AU2023201112B2/en active Active
-
2024
- 2024-06-26 US US18/755,253 patent/US20240423986A1/en active Pending
- 2024-11-07 JP JP2024195175A patent/JP2025026895A/ja active Pending
-
2025
- 2025-08-06 AU AU2025213576A patent/AU2025213576A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3452039T (lt) | Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriais | |
| IL263680A (en) | Combination therapies | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| IL263030A (en) | Pegylated liposomes and methods of use | |
| HUE056287T2 (hu) | Pancreatitis kezelése | |
| IL246678A0 (en) | Azepane derivatives and methods of treating hepatitis b infections | |
| EP3487523A4 (en) | THERAPEUTIC APPLICATIONS OF THE CPF1-BASED GENOME EDITION | |
| PL3283527T3 (pl) | Leczenie skojarzone nowotworów | |
| EP4212536C0 (en) | BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | |
| DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3285803T3 (da) | Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine | |
| DK3504187T3 (da) | Anvendelse af pridopidin til behandling af funktionel tilbagegang | |
| IL263802A (en) | Cancer treatment combinations | |
| PL3277270T3 (pl) | Kompozycje i sposoby leczenia niedokrwistości | |
| IL254876A0 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| PT3458052T (pt) | Tratamento combinado do cancro | |
| PL3289672T3 (pl) | Sposoby i urządzenia do tworzenia przeplatanych zespołów falistych cewek | |
| PL3493812T3 (pl) | Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| IL257764B (en) | Methods for treatment of diseases | |
| IL254825A0 (en) | Methods of treatment with taselisib | |
| DK3532076T3 (da) | Immunterapeutiske behandlinger af tumorer | |
| IL313083A (en) | Terlipressin compositions and their methods of use | |
| IL280343A (en) | Treatment of mucopolysaccharidosis iva |